KCPG
RARE icon

Kavar Capital Partners Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Kavar Capital Partners Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7
Closed – – 321
2015
Q4 		$0 Buy
7
+1
+17% +$100 ﹤0.01% 515
2015
Q3 		$0 Buy
6
+1
+20% +$114 ﹤0.01% 523
2015
Q2 		$0 Buy
+5
New +$388 ﹤0.01% 531

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kavar Capital Partners Group's RARE Position: Q1 2016 in Review

Kavar Capital Partners Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2016, closing a stake of 7 shares.

Kavar Capital Partners Group first reported a position in RARE in Q2 2015 and held it in 3 quarters. The position peaked at $0 in Q4 2015. 161 funds tracked by Wall St. Rank hold RARE as of Q1 2016.

  • Kavar Capital Partners Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2016 after selling out during the quarter.
  • Kavar Capital Partners Group sold 7 Ultragenyx Pharmaceutical shares in Q1 2016.
  • Kavar Capital Partners Group first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 3 quarters.
  • Kavar Capital Partners Group's Ultragenyx Pharmaceutical position peaked at $0 in Q4 2015.
  • 161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2016.

Based on Kavar Capital Partners Group's 13F filing for Q1 2016, filed 13 May 2019.